Deliver Your News to the World

Gesundís Platform for Immediately Generating Insights Into the Equity, Safety and Effectiveness of Medical AI Receives Acceptance to Merck Digital Sciences Studio

The news signals interest in Gesundís ability to evaluate AI tools for drug discovery along with clinical diagnostics in fields like radiology

Boston, MA – WEBWIRE

Gesund, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced acceptance into the Merck Digital Sciences Studio (MDSS). While terms of the participation are not being disclosed, the news signals support for the companyís approach mere months after debuting from stealth.

Gesund is building a picks and shovels platform for building, testing and validating medical AI. As a first market, the company is focusing on applications in radiology where algorithms and machine learning have made quick inroads thanks to the abundance of imaging - raw training data - inherent to the profession. Gesund is invaluable to what we AI developers are doing because it streamlines regulatory clearance efforts by running algorithms against case-specific data annotated by board-certified radiologists to generate regulatory-grade performance metrics within days instead of years.

ďIn a real sense medical AI didnít exist five years ago, so itís not surprising that validation and testing foundations like we are building are only now becoming robust and widespread,Ē observed Dr. Enes Hosgor, CEO and founder of Gesund. ďMachine learning platforms have revolutionized other industries with companies like Snowflake, and weíre looking forward to helping transform the critical sector of healthcare.Ē

The MDSS is a program that supports biomedical startups with direct investment, access to Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. Gesundís entrance into the MDSS is remarkable for the interest it signals for the broader uses the company can provide to the biopharmaceutical industry. By building a compliant picks-and-shovels MLOps platform that is agnostic to the underlying AI, developers can upload or register their algorithms and share with other collaborators in remote sites while also being able to run the same algorithm on proprietary datasets shared by other parties privately, all happening within the same platform with no PHI data exposed.

ďGesund is part of the next generation of companies realizing the promise and power of AI in healthcare,Ē said Geof Hannigan, Executive Director, Merck Digital Sciences Studio. ďThe value of a global healthcare partner like Merck encompasses arenas like business advice, clinical relationships and technical support and we are proud to help these companies more quickly make an outsized impact.Ē

The news builds on a busy year for the company since it debuted from stealth in March 2022. It will be exhibiting at the preeminent radiology conference and has partnered with a number of hospitals and is continuing to expand its operations teams as it sets its sights on more growth in 2023.

About Gesund

Gesund is building the highway of clinical-grade artificial intelligence.

The company connects highly curated and diverse data sets to medtech innovators so they can more quickly and efficiently build and test AI thatís effective and safe for clinical settings. Itís designed from the ground up to work in high compliance environments with no cloud access and to be used by doctors, researchers and other medical stakeholders through a simple low-code interface.

The company was founded by Enes Hosgor, Ph.D., in 2021 and is backed by marquee venture capitalists including 500 Global. For more information visit:



 Health Tech
 Clinical Ai
 Machine Learning

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.